Trial
NCT06084845
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Phase IIWITHDRAWNEFFICACY/FUTILITYConfidence: HIGH
Sponsor
ECOG-ACRIN Cancer Research Group
Collaborators
National Cancer Institute (NCI)
Condition
Head and Neck Squamous Cell Carcinoma
Intervention
Biospecimen Collection
Why stopped
A phase III trial of the investigational agent failed to pass futility boundaries at interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-25